Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial
- Resource Type
- Article
- Source
- In
eClinicalMedicine November 2023 65 - Subject
- Language
- ISSN
- 2589-5370